Pharmaceutical company Astellas Pharma Inc (TSE: 4503) and Osaka University have entered a research collaboration to develop a pluripotent stem cell-derived cartilage organoid cell therapy for intervertebral disc degenerative disease, Astellas Pharma revealed on Monday.
This partnership involves Astellas Institute for Regenerative Medicine (AIRM), Universal Cells (a subsidiary of Astellas), and Osaka University's Graduate School of Medicine.
Universal Cells' Universal Donor Cell (UDC) technology, which reduces immune rejection risks through gene editing of Human Leukocyte Antigen (HLA), will be a cornerstone of the project. The collaboration aims to combine the cartilage tissue creation protocol from Professor Noriyuki Tsumaki at Osaka University, UDC technology and AIRM's R&D expertise to create an innovative treatment for disc degeneration.
Astellas Pharma operates in over 70 countries, focusing on developing new drugs for diseases with high unmet medical needs and creating Rx+ healthcare solutions by integrating their expertise with advanced technology.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member